Zhuhai Gene Biocon Biological Technology Co., Ltd.

1. Product Description

Liraglutide is a glucagon-like peptide, which increases insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, delays gastric emptying, and reduces food intake through central appetite inhibition, thereby reducing blood sugar. In addition to effectively reducing blood sugar, weight loss and central obesity can be improved by suppressing appetite, reducing food intake, increasing satiety and energy consumption, delaying gastric emptying and gastrointestinal peristalsis. Liraglutide can be used either alone or in combination with other oral hypoglycemic agents and basic insulin. 

Liraglutide can reduce glycosylated hemoglobin, and it has been shown to be beneficial to cardiovascular treatment in type 2 diabetic patients with atherosclerotic cardiovascular disease with coronary heart disease, ischemic stroke, and peripheral artery disease.

2. Product Usage

Used to prepare liraglutide injection.

3. Product Advantage

a. Meet the requirements of GMP specification.

b. Complete quality documents.

4. Product Features

Appearances: White or off-white powder.

Activity: 70%~130%.

Content: 95.0%~105.0%.

Bacterial Endotoxin: Less than 10 EU/mg.

HPLC Purity: ＞98.0%.

5. Notice and Disclaimer

a. Pollution should be avoided during operation.

b. The product should not be used for diagnosis or treatment of animals or humans.